Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

The promise of genome editing to help understand human diseases and create new therapies is vast, but technological ...

A new study from the Norwegian Institute of Food, Fisheries, and Aquaculture Research (Nofima) has analyzed different salmon ...

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and ...

Working with data from the Fred Hutch Cancer Center, and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO ...

Researchers have found a promising new method for gene therapy. They successfully restarted inactive genes by bringing them closer to genetic switches ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

One way would be to ensure there is a consistent and predictable yield year by year. For two years in a row, beginning in the ...

Researchers from Waters and Biospring studied the contribution of nucleotide type and modifications on the retention and resolution of 22–24 nt long oligonucleotides in different chromatographic ...